

Healthy People 2010 Operational Definition

13-13. Increase the proportion of HIV-infected adolescents and adults who receive testing, treatment, and prophylaxis consistent with current Public Health Service treatment guidelines.

Prophylaxis

13-13e. Pneumocystis carinii pneumonia (PCP) prophylaxis.

National Data Source	Adult Spectrum of Disease (ASD) surveillance project, CDC, NCHSTP (11 U.S. cities—see Comments).
State Data Source	Not identified.
Healthy People 2000 Objective	Not applicable.
Changes since the 2000 Publication	None.
Measure	Percent.
Baseline (Year)	81 (1997) (selected sites—see Comments).
Target	95
Target-Setting Method	An improvement to the same percentage as that projected for <i>Pneumocystis carinii pneumonia</i> prophylaxis. For a discussion of target-setting methods, see Part A, section 4.
Numerator	Number of persons enrolled in the ASD surveillance project with at least one clinic visit, had no history of PCP, had a minimum cd4 cell count of less than 200, and received any appropriate PCP prophylaxis, all in the past year.
Denominator	Number of persons enrolled in the ASD surveillance project with at least one clinic visit, had no history of PCP, and had a minimum cd4 cell count of less than 200 in the past year.
Population Targeted	Residents of selected sites—see Comments.

Questions Used To Obtain the National Baseline Data

Not applicable.

Expected Periodicity

Annual.

Comments

PCP prophylaxis is defined as medications (trimethoprim-sulfamethoxazole, dapsone, or aerosolized pentamidine) given to prevent the occurrence of PCP. The case definition of PCP is provided by CDC.¹

ASD data were standardized to national AIDS surveillance data for 1997 by age, race, sex, country of birth, year of AIDS diagnosis, and HIV exposure mode. Exposure modes in AIDS surveillance were redistributed to adjust for cases with risk that were not reported or identified.

ASD data represent more than 100 sites in 11 U.S. cities. ASD collects demographic, clinical, laboratory, surveillance, and other related data on HIV-infected persons aged 13 years and older.

Data from ASD represent only persons with HIV who are in care at participating ASD facilities. Treatment interventions include viral load testing, TB skin testing, HAART, PCP prophylaxis, MAC prophylaxis, and pneumococcal vaccination.

The original 1997 baseline of 80 percent was revised to 81 percent after the Healthy People 2010 Midcourse Review. The original target of 95 percent did not change.

See Appendix A for focus area contact information.

References

1. CDC. *Morbidity and Mortality Weekly Report* 41(RR-17):1-19, 1992.